Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial
Oral fluoropyrimidines are used for the first-line treatment of metastatic breast cancer to avoid severe adverse effects, although firm supporting evidence is lacking. We aimed to establish whether S-1 is non-inferior to taxanes in this setting.
Gespeichert in:
| Autor*in: |
Takashima, Tsutomu [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016 |
|---|
| Umfang: |
9 |
|---|
| Übergeordnetes Werk: |
Enthalten in: My - Citovsky, Vitaly ELSEVIER, 2019, London |
|---|---|
| Übergeordnetes Werk: |
volume:17 ; year:2016 ; number:1 ; pages:90-98 ; extent:9 |
| Links: |
|---|
| DOI / URN: |
10.1016/S1470-2045(15)00411-8 |
|---|
| Katalog-ID: |
ELV013751921 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV013751921 | ||
| 003 | DE-627 | ||
| 005 | 20230623110829.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1470-2045(15)00411-8 |2 doi | |
| 028 | 5 | 2 | |a GBVA2016004000005.pica |
| 035 | |a (DE-627)ELV013751921 | ||
| 035 | |a (ELSEVIER)S1470-2045(15)00411-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 570 |q VZ |
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 084 | |a 35.70 |2 bkl | ||
| 084 | |a 42.12 |2 bkl | ||
| 100 | 1 | |a Takashima, Tsutomu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial |
| 264 | 1 | |c 2016 | |
| 300 | |a 9 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Oral fluoropyrimidines are used for the first-line treatment of metastatic breast cancer to avoid severe adverse effects, although firm supporting evidence is lacking. We aimed to establish whether S-1 is non-inferior to taxanes in this setting. | ||
| 700 | 1 | |a Mukai, Hirofumi |4 oth | |
| 700 | 1 | |a Hara, Fumikata |4 oth | |
| 700 | 1 | |a Matsubara, Nobuaki |4 oth | |
| 700 | 1 | |a Saito, Tsuyoshi |4 oth | |
| 700 | 1 | |a Takano, Toshimi |4 oth | |
| 700 | 1 | |a Park, Youngjin |4 oth | |
| 700 | 1 | |a Toyama, Tatsuya |4 oth | |
| 700 | 1 | |a Hozumi, Yasuo |4 oth | |
| 700 | 1 | |a Tsurutani, Junji |4 oth | |
| 700 | 1 | |a Imoto, Shigeru |4 oth | |
| 700 | 1 | |a Watanabe, Takanori |4 oth | |
| 700 | 1 | |a Sagara, Yoshiaki |4 oth | |
| 700 | 1 | |a Nishimura, Reiki |4 oth | |
| 700 | 1 | |a Shimozuma, Kojiro |4 oth | |
| 700 | 1 | |a Ohashi, Yasuo |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n The Lancet Publ. Group |a Citovsky, Vitaly ELSEVIER |t My |d 2019 |g London |w (DE-627)ELV003173852 |
| 773 | 1 | 8 | |g volume:17 |g year:2016 |g number:1 |g pages:90-98 |g extent:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S1470-2045(15)00411-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 35.70 |j Biochemie: Allgemeines |q VZ |
| 936 | b | k | |a 42.12 |j Biophysik |q VZ |
| 951 | |a AR | ||
| 952 | |d 17 |j 2016 |e 1 |h 90-98 |g 9 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
t t tt |
|---|---|
| matchkey_str |
takashimatsutomumukaihirofumiharafumikat:2016----:aaevrusateislnceohrpfreattcratacreetcnpnaennn |
| hierarchy_sort_str |
2016 |
| bklnumber |
35.70 42.12 |
| publishDate |
2016 |
| allfields |
10.1016/S1470-2045(15)00411-8 doi GBVA2016004000005.pica (DE-627)ELV013751921 (ELSEVIER)S1470-2045(15)00411-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Takashima, Tsutomu verfasserin aut Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial 2016 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Oral fluoropyrimidines are used for the first-line treatment of metastatic breast cancer to avoid severe adverse effects, although firm supporting evidence is lacking. We aimed to establish whether S-1 is non-inferior to taxanes in this setting. Mukai, Hirofumi oth Hara, Fumikata oth Matsubara, Nobuaki oth Saito, Tsuyoshi oth Takano, Toshimi oth Park, Youngjin oth Toyama, Tatsuya oth Hozumi, Yasuo oth Tsurutani, Junji oth Imoto, Shigeru oth Watanabe, Takanori oth Sagara, Yoshiaki oth Nishimura, Reiki oth Shimozuma, Kojiro oth Ohashi, Yasuo oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:17 year:2016 number:1 pages:90-98 extent:9 https://doi.org/10.1016/S1470-2045(15)00411-8 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 17 2016 1 90-98 9 045F 610 |
| spelling |
10.1016/S1470-2045(15)00411-8 doi GBVA2016004000005.pica (DE-627)ELV013751921 (ELSEVIER)S1470-2045(15)00411-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Takashima, Tsutomu verfasserin aut Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial 2016 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Oral fluoropyrimidines are used for the first-line treatment of metastatic breast cancer to avoid severe adverse effects, although firm supporting evidence is lacking. We aimed to establish whether S-1 is non-inferior to taxanes in this setting. Mukai, Hirofumi oth Hara, Fumikata oth Matsubara, Nobuaki oth Saito, Tsuyoshi oth Takano, Toshimi oth Park, Youngjin oth Toyama, Tatsuya oth Hozumi, Yasuo oth Tsurutani, Junji oth Imoto, Shigeru oth Watanabe, Takanori oth Sagara, Yoshiaki oth Nishimura, Reiki oth Shimozuma, Kojiro oth Ohashi, Yasuo oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:17 year:2016 number:1 pages:90-98 extent:9 https://doi.org/10.1016/S1470-2045(15)00411-8 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 17 2016 1 90-98 9 045F 610 |
| allfields_unstemmed |
10.1016/S1470-2045(15)00411-8 doi GBVA2016004000005.pica (DE-627)ELV013751921 (ELSEVIER)S1470-2045(15)00411-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Takashima, Tsutomu verfasserin aut Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial 2016 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Oral fluoropyrimidines are used for the first-line treatment of metastatic breast cancer to avoid severe adverse effects, although firm supporting evidence is lacking. We aimed to establish whether S-1 is non-inferior to taxanes in this setting. Mukai, Hirofumi oth Hara, Fumikata oth Matsubara, Nobuaki oth Saito, Tsuyoshi oth Takano, Toshimi oth Park, Youngjin oth Toyama, Tatsuya oth Hozumi, Yasuo oth Tsurutani, Junji oth Imoto, Shigeru oth Watanabe, Takanori oth Sagara, Yoshiaki oth Nishimura, Reiki oth Shimozuma, Kojiro oth Ohashi, Yasuo oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:17 year:2016 number:1 pages:90-98 extent:9 https://doi.org/10.1016/S1470-2045(15)00411-8 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 17 2016 1 90-98 9 045F 610 |
| allfieldsGer |
10.1016/S1470-2045(15)00411-8 doi GBVA2016004000005.pica (DE-627)ELV013751921 (ELSEVIER)S1470-2045(15)00411-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Takashima, Tsutomu verfasserin aut Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial 2016 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Oral fluoropyrimidines are used for the first-line treatment of metastatic breast cancer to avoid severe adverse effects, although firm supporting evidence is lacking. We aimed to establish whether S-1 is non-inferior to taxanes in this setting. Mukai, Hirofumi oth Hara, Fumikata oth Matsubara, Nobuaki oth Saito, Tsuyoshi oth Takano, Toshimi oth Park, Youngjin oth Toyama, Tatsuya oth Hozumi, Yasuo oth Tsurutani, Junji oth Imoto, Shigeru oth Watanabe, Takanori oth Sagara, Yoshiaki oth Nishimura, Reiki oth Shimozuma, Kojiro oth Ohashi, Yasuo oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:17 year:2016 number:1 pages:90-98 extent:9 https://doi.org/10.1016/S1470-2045(15)00411-8 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 17 2016 1 90-98 9 045F 610 |
| allfieldsSound |
10.1016/S1470-2045(15)00411-8 doi GBVA2016004000005.pica (DE-627)ELV013751921 (ELSEVIER)S1470-2045(15)00411-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Takashima, Tsutomu verfasserin aut Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial 2016 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Oral fluoropyrimidines are used for the first-line treatment of metastatic breast cancer to avoid severe adverse effects, although firm supporting evidence is lacking. We aimed to establish whether S-1 is non-inferior to taxanes in this setting. Mukai, Hirofumi oth Hara, Fumikata oth Matsubara, Nobuaki oth Saito, Tsuyoshi oth Takano, Toshimi oth Park, Youngjin oth Toyama, Tatsuya oth Hozumi, Yasuo oth Tsurutani, Junji oth Imoto, Shigeru oth Watanabe, Takanori oth Sagara, Yoshiaki oth Nishimura, Reiki oth Shimozuma, Kojiro oth Ohashi, Yasuo oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:17 year:2016 number:1 pages:90-98 extent:9 https://doi.org/10.1016/S1470-2045(15)00411-8 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 17 2016 1 90-98 9 045F 610 |
| language |
English |
| source |
Enthalten in My London volume:17 year:2016 number:1 pages:90-98 extent:9 |
| sourceStr |
Enthalten in My London volume:17 year:2016 number:1 pages:90-98 extent:9 |
| format_phy_str_mv |
Article |
| bklname |
Biochemie: Allgemeines Biophysik |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
My |
| authorswithroles_txt_mv |
Takashima, Tsutomu @@aut@@ Mukai, Hirofumi @@oth@@ Hara, Fumikata @@oth@@ Matsubara, Nobuaki @@oth@@ Saito, Tsuyoshi @@oth@@ Takano, Toshimi @@oth@@ Park, Youngjin @@oth@@ Toyama, Tatsuya @@oth@@ Hozumi, Yasuo @@oth@@ Tsurutani, Junji @@oth@@ Imoto, Shigeru @@oth@@ Watanabe, Takanori @@oth@@ Sagara, Yoshiaki @@oth@@ Nishimura, Reiki @@oth@@ Shimozuma, Kojiro @@oth@@ Ohashi, Yasuo @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
ELV003173852 |
| dewey-sort |
3610 |
| id |
ELV013751921 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV013751921</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623110829.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(15)00411-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016004000005.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV013751921</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(15)00411-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Takashima, Tsutomu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Oral fluoropyrimidines are used for the first-line treatment of metastatic breast cancer to avoid severe adverse effects, although firm supporting evidence is lacking. We aimed to establish whether S-1 is non-inferior to taxanes in this setting.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mukai, Hirofumi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hara, Fumikata</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matsubara, Nobuaki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Saito, Tsuyoshi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takano, Toshimi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Park, Youngjin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Toyama, Tatsuya</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hozumi, Yasuo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tsurutani, Junji</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Imoto, Shigeru</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Watanabe, Takanori</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sagara, Yoshiaki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nishimura, Reiki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shimozuma, Kojiro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ohashi, Yasuo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:90-98</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(15)00411-8</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">2016</subfield><subfield code="e">1</subfield><subfield code="h">90-98</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Takashima, Tsutomu |
| spellingShingle |
Takashima, Tsutomu ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial |
| authorStr |
Takashima, Tsutomu |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV003173852 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 570 - Life sciences; biology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial |
| topic |
ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
| topic_unstemmed |
ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
| topic_browse |
ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
h m hm f h fh n m nm t s ts t t tt y p yp t t tt y h yh j t jt s i si t w tw y s ys r n rn k s ks y o yo |
| hierarchy_parent_title |
My |
| hierarchy_parent_id |
ELV003173852 |
| dewey-tens |
610 - Medicine & health 570 - Life sciences; biology |
| hierarchy_top_title |
My |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV003173852 |
| title |
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial |
| ctrlnum |
(DE-627)ELV013751921 (ELSEVIER)S1470-2045(15)00411-8 |
| title_full |
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial |
| author_sort |
Takashima, Tsutomu |
| journal |
My |
| journalStr |
My |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
90 |
| author_browse |
Takashima, Tsutomu |
| container_volume |
17 |
| physical |
9 |
| class |
610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Takashima, Tsutomu |
| doi_str_mv |
10.1016/S1470-2045(15)00411-8 |
| dewey-full |
610 570 |
| title_sort |
taxanes versus s-1 as the first-line chemotherapy for metastatic breast cancer (select bc): an open-label, non-inferiority, randomised phase 3 trial |
| title_auth |
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial |
| abstract |
Oral fluoropyrimidines are used for the first-line treatment of metastatic breast cancer to avoid severe adverse effects, although firm supporting evidence is lacking. We aimed to establish whether S-1 is non-inferior to taxanes in this setting. |
| abstractGer |
Oral fluoropyrimidines are used for the first-line treatment of metastatic breast cancer to avoid severe adverse effects, although firm supporting evidence is lacking. We aimed to establish whether S-1 is non-inferior to taxanes in this setting. |
| abstract_unstemmed |
Oral fluoropyrimidines are used for the first-line treatment of metastatic breast cancer to avoid severe adverse effects, although firm supporting evidence is lacking. We aimed to establish whether S-1 is non-inferior to taxanes in this setting. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA |
| container_issue |
1 |
| title_short |
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial |
| url |
https://doi.org/10.1016/S1470-2045(15)00411-8 |
| remote_bool |
true |
| author2 |
Mukai, Hirofumi Hara, Fumikata Matsubara, Nobuaki Saito, Tsuyoshi Takano, Toshimi Park, Youngjin Toyama, Tatsuya Hozumi, Yasuo Tsurutani, Junji Imoto, Shigeru Watanabe, Takanori Sagara, Yoshiaki Nishimura, Reiki Shimozuma, Kojiro Ohashi, Yasuo |
| author2Str |
Mukai, Hirofumi Hara, Fumikata Matsubara, Nobuaki Saito, Tsuyoshi Takano, Toshimi Park, Youngjin Toyama, Tatsuya Hozumi, Yasuo Tsurutani, Junji Imoto, Shigeru Watanabe, Takanori Sagara, Yoshiaki Nishimura, Reiki Shimozuma, Kojiro Ohashi, Yasuo |
| ppnlink |
ELV003173852 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/S1470-2045(15)00411-8 |
| up_date |
2024-07-06T19:43:27.198Z |
| _version_ |
1803860057467650048 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV013751921</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623110829.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(15)00411-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016004000005.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV013751921</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(15)00411-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Takashima, Tsutomu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Oral fluoropyrimidines are used for the first-line treatment of metastatic breast cancer to avoid severe adverse effects, although firm supporting evidence is lacking. We aimed to establish whether S-1 is non-inferior to taxanes in this setting.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mukai, Hirofumi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hara, Fumikata</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matsubara, Nobuaki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Saito, Tsuyoshi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takano, Toshimi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Park, Youngjin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Toyama, Tatsuya</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hozumi, Yasuo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tsurutani, Junji</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Imoto, Shigeru</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Watanabe, Takanori</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sagara, Yoshiaki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nishimura, Reiki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shimozuma, Kojiro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ohashi, Yasuo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:90-98</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(15)00411-8</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">2016</subfield><subfield code="e">1</subfield><subfield code="h">90-98</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4000244 |